Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for cardiovascular, metabolic, and liver diseases. Their primary focus has been on non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease. Madrigal's lead product candidate, Rezdiffra™ (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor (THR)-β selective agonist. In March 2024, Rezdiffra received FDA approval for the treatment of adult patients with noncirrhotic NASH with moderate to advanced liver fibrosis, making it the first and only medication approved for this indication. The company is committed to addressing significant unmet medical needs and improving patient outcomes through pioneering science.
Serves as the central hub for all corporate, strategic, research and development oversight, and commercial operations.
Modern office facilities located within a suburban business park, designed to support administrative functions, clinical development oversight, and commercialization planning.
The headquarters fosters a dynamic, science-driven, and collaborative work environment. There is a strong emphasis on innovation, patient-centricity, and achieving milestones, particularly as the company transitions into a commercial-stage entity.
The headquarters is critical for Madrigal's operations, housing its leadership team and centralizing decision-making for its clinical programs, regulatory strategies, and the commercial launch of Rezdiffra™.
Madrigal Pharmaceuticals' global presence has primarily been characterized by its international clinical trial sites for Rezdiffra™. With FDA approval secured in the U.S., the initial commercial focus is on the American market. The company may pursue regulatory approvals and commercialization in other key international regions in the future, expanding its global operational footprint for medical affairs, market access, and sales.
200 Barr Harbor Drive, Suite 200
West Conshohocken
PA
United States
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Madrigal Pharmaceuticals' leadership includes:
Madrigal Pharmaceuticals has been backed by several prominent investors over the years, including:
Madrigal Pharmaceuticals has significantly bolstered its executive team in the past 12 months, appointing a new CEO, COO, and CLCO. These changes align with the company's strategic evolution into a commercial-stage organization following the landmark FDA approval of Rezdiffra™. Dr. Paul Friedman transitioned from CEO to Chairman of the Board, ensuring continuity of leadership.
Discover the tools Madrigal Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Madrigal Pharmaceuticals Inc. likely utilizes common corporate email formats. Based on industry standards and observed patterns for executives, one of the probable primary formats is the first initial followed by the last name.
[first_initial][last]@madrigalpharma.com
Format
jdoe@madrigalpharma.com
Example
75%
Success rate
ir.madrigalpharma.com • March 14, 2024
Madrigal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra™ (resmetirom) for the treatment of adult patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Rezdiffra is the first and only once-daily, oral medication approved for NASH....more
ir.madrigalpharma.com • May 8, 2024
Madrigal Pharmaceuticals reported its financial results for the first quarter ended March 31, 2024, and provided an update on the U.S. commercial launch of Rezdiffra™, as well as other corporate developments. The company highlighted its focus on ensuring patient access and physician education for its newly approved NASH treatment....more
ir.madrigalpharma.com • June 5, 2024
Madrigal announced new data presentations for Rezdiffra™ (resmetirom) at the European Association for the Study of the Liver (EASL) Congress 2024. The presentations included further analyses from the pivotal Phase 3 MAESTRO-NASH trial, reinforcing the drug's efficacy in resolving NASH and improving liver fibrosis, alongside its generally well-tolerated safety profile....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Madrigal Pharmaceuticals, are just a search away.